Abstract
Brucella, a genus of bacteria that causes brucellosis, infects and threatens domestic animals, and humans in endemic areas. Presently, some live attenuated vaccines of Brucella are used to immunize livestock; however, these vaccines are pathogenic to humans, can provoke abortion when administered to pregnant livestock, and induce antibodies in vaccinated livestock that affect the diagnosis of field infection. It is, therefore, very important for improving the safety and immune protection effects of Brucella vaccine. Currently, recombinant protein-based subunit vaccines are considered promising safe and effective alternatives against brucellosis. Here, we separately expressed the recombinant Omp10-Omp28-L7/L12 proteins of Brucella using eukaryotic and prokaryotic expression systems, which were then used as immunogens for evaluating their immune responses. Taishan Pinus massoniana pollen polysaccharides (TPPPS), an already verified natural adjuvant, was utilized to evaluate the immune conditioning effect on the recombinant proteins. Antibody levels, spleen lymphocyte proliferation, percentages of CD4+ and CD8+ T cells, and cytokine secretion in mice were examined after three successive immunizations. The protective effects against Brucella challenge were also evaluated in mice, and used a live vaccine as a positive control. The results indicated that the immune responses of the recombinant Omp10-Omp28-L7/L12 protein groups were significantly higher than those of the PBS control group. The recombinant Omp10-Omp28-L7/L12 protein expressed in Pichia pastoris (P. pastoris) exhibited a slightly higher expression level and immunogenicity than that expressed in Escherichia coli (E. coli), and the Omp10-Omp28-L7/L12 (P. pastoris) + TPPPS group provided the most pronounced immune effect. The protective results showed that the recombinant Omp10-Omp28-L7/L12 proteins expressed in the two expression systems had significantly better protective effects against Brucella melitensis challenge compared with the negative control, and the addition of TPPPS adjuvant could significantly improve the protective effects of subunit vaccines. However, we also noticed that all of the evaluated subunit vaccines induced less protection than the B. melitensis M5 live vaccine. These results indicate that the combination of recombinant Omp10-Omp28-L7/L12 antigen and TPPPS adjuvant shows potential as an effective brucellosis subunit vaccine, and P. pastoris is a preferred expression system to prepare this recombinant subunit antigen.
Highlights
Brucellosis is a common zoonosis caused by certain species of the Brucella genus, which are facultative, intracellular, Gramnegative pathogens [1]
The results indicate that the recombinant Omp10-Omp28-L7/L12 subunit antigens induce positive immune responses and protective effects against Brucella, and the protective effects and immunogenicity of the recombinant Omp10-Omp28-L7/L12 protein expressed in the eukaryotic system have advantages compared to those of the prokaryotic Omp10-Omp28-L7/L12 recombinant protein
Simborio et al showed that the combined rOmp antigens have good reactivity for diagnosing disease and provide protection against B. abortus infection [11]; Golshani et al found that rL7/L12-TOmp31 can induce a strong IgG response compared with a single protein [25]; Ghasemi et al demonstrated that a recombinant antigen containing rOmp31 + rTF provides a high level of protection against B. melitensis, which makes it a good candidate for the development of a multivalent subunit vaccine [50]
Summary
Brucellosis is a common zoonosis caused by certain species of the Brucella genus, which are facultative, intracellular, Gramnegative pathogens [1]. The live brucellosis vaccines can effectively reduce the prevalence of brucellosis in natural hosts, but with known disadvantages: [1] they are unstable and sometimes cause brucellosis associated with vaccines; [2] we cannot distinguish between vaccine reactions and natural infections using antibody detection; [3] some live vaccines can cause allergic reactions similar to strong Brucella infection; and [4] some live Brucella vaccines cannot be used in pregnant or lactating animals [7] For these reasons, new strategies or improved vaccines against Brucella must be developed
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
